CLINICAL AND LABORATORY STANDARDS INSTITUTE®

5th Edition

M39

Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data

This guideline describes methods for recording and analyzing antimicrobial susceptibility test data, consisting of cumulative and ongoing summaries of susceptibility patterns of clinically significant microorganisms.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

M39-Ed5
January 2022
Replaces M39-A4

Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data

Janet A. Hindler, MCLS, MT(ASCP), F(AAM)
Patricia J. Simner, PhD, D(ABMM)
April Abbott, PhD, (ABMM)
Faiza H. Benahmed, MS
Tanaya Bhowmick, MD
Sanchita Das, MD, D(ABMM)
Sharon M. Erdman, PharmD, FIDP
Andrea L. Ferrell, MLS^{CM}(ASCP)
Kristie Johnson, PhD, D(ABMM)
Brian V. Lubbers, DVM, PhD, DACVCP
Ron Master, SM(AAM)
Jimish M. Mehta, PharmD, MSCE
Ian Morrissey, BSc, MBA, PhD, FRSM
Mark A. Redell, PharmD
Helio S. Sader, MD
Dawn M. Sievert, PhD, MS
Paula M. Snippes Vagnone, MT(ASCP)
John Stelling, MD, MPH

Abstract

Susceptibility statistical data, consisting of the cumulative and ongoing summary of the antimicrobial susceptibility patterns of clinically important microorganisms, are important to the practice of medicine on several levels. If the methods used to create, record, and analyze the data are not reliable and consistent, many of the most important applications and benefits of the data will not be realized. Clinical and Laboratory Standards Institute document M39—*Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data* provides guidelines for medical laboratories and data analysis software providers for the routine generation and storage of susceptibility data and for the compilation of susceptibility statistics. This guideline also provides suggestions for medical laboratories, clinicians, and others involved in antimicrobial stewardship on effective use of their cumulative susceptibility statistics when empirical antimicrobial therapy is selected.

Clinical and Laboratory Standards Institute (CLSI). *Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data.* 5th ed. CLSI guideline M39 (ISBN 978-1-68440-132-1 [Print]; ISBN 978-1-68440-133-8 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2022.

CLINICAL AND LABORATORY STANDARDS INSTITUTE®

Suggested Citation

CLSI. *Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data.* 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute; 2022.

Previous Editions:
December 2000, May 2002, November 2005, February 2009, January 2014

M39-Ed5
ISBN 978-1-68440-132-1 (Print)
ISBN 978-1-68440-133-8 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
Volume 42, Number 1

Committee Membership

Consensus Council

James R. Petisce, PhD
Chairholder
BD Diagnostic Systems
USA

Tania Motschman, MS, MT(ASCP)SBB
Vice-Chairholder
USA

Deirdre Astin, MS, MT(ASCP)
USA

Anne T. Daley, MS, MT(ASCP)DLM, CMQ/OE(ASQ)CSBB
USA

Avis Danishefsky, PhD
FDA Center for Devices and Radiological Health
USA

Collette Fitzgerald, PhD
Centers for Disease Control and Prevention
USA

Michelle McLean, MS, MT(ASCP), BS
Greiner Bio-One, Inc.
USA

James H. Nichols, PhD, DABCC, FAACC
Vanderbilt University School of Medicine
USA

M. Laura Parnas, PhD, DABCC
Roche Diagnostics
USA

Victoria Petrides, MS
Abbott
USA

Matthew A. Wikler, MD, FIDSA, MBA
IDTD Consulting
USA

Subcommittee on Antimicrobial Susceptibility Testing

James S. Lewis II, PharmD, FIDSA
Chairholder
Oregon Health and Science University
USA

Melvin P. Weinstein, MD
Vice-Chairholder
Rutgers Robert Wood Johnson University Hospital
USA

Sharon K. Cullen, BS, RAC
Beckman Coulter, Inc., Microbiology Business
USA

Marcelo F. Galas, BSc
Pan American Health Organization
USA

Howard Gold, MD, FIDSA
Beth Israel Deaconess Medical Center
USA

Romney M. Humphries, PhD, D(ABMM)
Vanderbilt University Medical Center
USA

Thomas J. Kirn Jr., MD, PhD
Rutgers Robert Wood Johnson Medical School
USA

Prashi Kumbago, PhD
Centers for Disease Control and Prevention
USA

Amy J. Mathers, MD, D(ABMM)
University of Virginia Medical Center
USA

Tony Mazzulli, MD, FACP, FRCP(C)
Sinai Health System
Canada

Sandra S. Richter, MD, D(ABMM), FIDSA
bioMérieux, Inc.
USA

Michael Satlin, MD, MS
New York Presbyterian Hospital
USA

Audrey N. Schuetz, MD, MPH, D(ABMM)
Mayo Clinic
USA

Patricia J. Simner, PhD, D(ABMM)
Johns Hopkins School of Medicine – Department of Pathology
USA

Expert Panel on Microbiology

Jean B. Patel, PhD, D(ABMM)
Chairholder
Beckman Coulter
USA

Audrey N. Schuetz, MD, MPH, D(ABMM)
Vice-Chairholder
Mayo Clinic
USA

Kevin Alby, PhD, D(ABMM)
University of North Carolina
USA

Esther Babady, PhD, D(ABMM)
Memorial Sloan Kettering Cancer Center
USA

Karissa Culbreath, PhD, D(ABMM)
University of New Mexico
Department of Pathology
USA

Marcelo F. Galas, BSc
Pan American Health Organization
USA

Shawn R. Lockhart, PhD, D(ABMM), F(AAM)
Centers for Disease Control and Prevention
USA

Brian V. Lubbers, DVM, PhD, DACVCP
Kansas State Veterinary Diagnostic Laboratory
USA

Margie Morgan, PhD, D(ABMM)
Cedars-Sinai Medical Center
USA

Sandra S. Richter, MD, D(ABMM), FIDSA
bioMérieux, Inc.
USA

Susan Sharp, PhD, D(ABMM), F(AAM)
Copan Diagnostics, Inc.
USA

Ribhi M. Shawar, PhD, D(ABMM), F(AAM)
FDA Center for Devices and Radiological Health
USA

Working Group on Cumulative AST Data Analysis

Janet A. Hindler, MCLS, MT(ASCP), F(AAM)
Co-Chairholder
Los Angeles County Department of Health
USA

Patricia J. Simner, PhD, D(ABMM)
Co-Chairholder
Johns Hopkins University School of Medicine – Department of Pathology
USA

April Abbott, PhD, D(ABMM)
Committee Secretary
Deaconess Hospital Laboratory
USA

Faiza H. Benahmed, MS
FDA Center for Devices and Radiological Health
USA

Tanaya Bhowmick, MS
Rutgers Robert Wood Johnson Medical School
USA

Sanchita Das, MD, D(ABMM)
National Institutes of Health, Department of Laboratory Medicine
USA

Sharon M. Erdman, PharmD, FIDP
Purdue University College of Pharmacy/Eskenazi Health
USA

Andrea L. Ferrell, MLS(CM)(ASCP)
Becton Dickinson
USA

Kristie Johnson, PhD, D(ABMM)
University of Maryland, Baltimore
USA

Brian V. Lubbers, DVM, PhD, DACVCP
Kansas State Veterinary Diagnostic Laboratory
USA

Ron Master, SM(AAM)
Quest Diagnostics Nichols Institute
USA

Jimish M. Mehta, PharmD, MSCE
CSL Behring
USA

John Morrissey, BsC, MBA, PhD, FRSM
IHMA Europe Särl
Switzerland

Mark A. Redell, PharmD
Melinta Therapeutics
USA

Helio S. Sader, MD
JMI Laboratories
USA

Dawn M. Sievert, PhD, MS
Centers for Disease Control and Prevention
USA

Paula M. Snippes Vagnone, MT(ASCP)
Minnesota Department of Health
USA

John Stelling, MD, MPH
Brigham and Women's Hospital – Microbiology
USA

Staff

Clinical and Laboratory Standards Institute
USA

Marcy L. Hackenbrack, MCM, M(ASCP)
Project Manager

Laura Martin
Editorial Manager

Catherine E.M. Jenkins, ELS
Editor

Kristy L. Leirer, MS
Editor

This page is intentionally left blank.

Contents

Contents (Continued)

Contents (Continued)

Contents (Continued)

Foreword

Cumulative results from antimicrobial susceptibility tests performed on individual patients' microbial isolates can be useful when compiled and reported at regular intervals. For a cumulative report (eg, antibiogram) to be compared with reports from previous years or from other facilities, data need to be analyzed and presented in a clear and consistent manner.

The primary aim of M39 is to guide the preparation and use of antibiograms by clinicians for selecting the most appropriate antimicrobial agents for empirical therapy for initial infections when definitive antimicrobial susceptibility test results are not available. Various types of cumulative antimicrobial susceptibility test data reports are used to support antimicrobial stewardship and infection prevention efforts. In addition, cumulative antimicrobial susceptibility test data may be of value to researchers when antimicrobial resistance is assessed.

Since the last edition of this guideline, there have been many changes in public health and medical microbiology laboratories with the introduction of rapid diagnostic tools (eg, multiplex molecular panels) and advanced informatics. Furthermore, there has been an increased emphasis on antimicrobial stewardship and public health initiatives to help contend with the global health threat of antimicrobial resistant microorganisms. Therefore, many of the changes in this guideline reflect how the antibiogram and other types of cumulative antimicrobial susceptibility test data reports can support these needs.

Overview of Changes

This guideline replaces the previous edition of the approved guideline, M39-A4, published in 2014. Several changes were made in this edition, including:

- Adding definitions for "cumulative antimicrobial susceptibility test data report" and "antibiogram"
- Adding considerations for extracting data from different sources (eg, automated antimicrobial susceptibility testing instrument, LIS, electronic health record) for antibiogram preparation
- Combining results from rapid diagnostics and antimicrobial resistance marker testing with the antibiogram for empirical therapy selection
- Developing antibiograms for yeast and antifungal agents
- Developing antibiograms for multiple facilities, long-term care facilities, and veterinary practices
- Describing ways in which antimicrobial stewardship programs may use antibiogram data
- Adding considerations for preparing cumulative antimicrobial susceptibility test data for peer-reviewed publication
- Using statistical analysis techniques including the calculation of percentiles, interquartile ranges, minimal inhibitory concentration (MIC) required to inhibit the growth of 50% of the organisms (MIC_{50}), and MIC required to inhibit the growth of 90% of the organisms (MIC_{90})
- Adding general comment explaining the use of the "^" with intermediate breakpoints for applicable antimicrobial agents known to have the ability to concentrate in the urine
- Deleting recommendation to list percent intermediate in addition to percent susceptible for penicillin with viridans group streptococci

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

Antibiogram

Antimicrobial agent

Antimicrobial resistance

Antimicrobial stewardship

Cumulative antibiogram

Epidemiology

Part I. Introduction and Data Acquisition

Chapter 1

Introduction

Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data

Part I. Introduction and Data Acquisition

1 Introduction

1.1 Scope

This guideline provides individuals involved with assessment of cumulative antimicrobial susceptibility test data with recommendations for the storage, analysis, and presentation of the data. The antimicrobial susceptibility test data from individual patient's isolates available for analysis are assumed to be final, accurate and in a usable format for health care providers. Recommendations cover the preparation of reports (eg, routine and enhanced antibiograms) to guide selection of empirical antimicrobial therapy. Reference to preparation of reports for other purposes is briefly discussed. This guideline is intended for use by individuals involved with:

- Analyzing and presenting cumulative antimicrobial susceptibility test data generated from testing microbial isolates from both humans and animals from single or multiple facilities (eg, clinical microbiologists, pharmacists, physicians, veterinarians, epidemiologists, infection prevention practitioners)
- Using antibiograms and other types of cumulative antimicrobial susceptibility test data to make clinical decisions, participate in antimicrobial stewardship programs, and/or participate in public health initiatives (eg, clinical microbiologists, infectious diseases specialists and other clinicians, infection prevention practitioners, pharmacists, epidemiologists, other health care personnel, and public health officials)
- Designing information systems for the storage and analysis of antimicrobial susceptibility test data (eg, LIS vendors, electronic health record [EHR] vendors, manufacturers of diagnostic products that include epidemiology analysis software, and manufacturers of epidemiology analysis or surveillance software)

This guideline does not include procedures for selecting isolates for antimicrobial susceptibility testing (AST), performing AST, interpreting AST results, nor confirming the accuracy of AST results.

1.2 Background

This guideline presents specific recommendations for collection, analysis, and presentation of cumulative antimicrobial susceptibility test data.

It is important to recognize that many of the specific recommendations presented for routine antibiogram development (eg, including only the first isolate of a given species from an individual patient during the analysis period) are made with the primary aim of guiding clinicians in the selection of empirical antimicrobial therapy for initial infections when definitive susceptibility results are not available. This report may not reveal some trends in emerging resistance, and thus cannot be used as a substitute for the careful analysis of all antimicrobial susceptibility test data derived from examining and/or analyzing all antimicrobial susceptibility test results obtained for individual patient management. For reports intended for purposes other than guiding empirical therapy (eg, identifying emergence of resistance, trending antimicrobial resistance for public health initiatives), alternative analyses may be more appropriate, and these are discussed briefly in this guideline, primarily in Subchapter 6.6.